• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

尿动力学作为米拉贝隆治疗结局的预测因子。

Urodynamics as a Prognosticator of Mirabegron Treatment Outcomes.

机构信息

Department of Women´s and Children´s Health, Karolinska Institutet, Stockholm, Sweden.

Department of Clinical Sciences, Karolinska Institutet Danderyd Hospital, Stockholm, Sweden.

出版信息

Gynecol Obstet Invest. 2019;84(5):472-476. doi: 10.1159/000496606. Epub 2019 Mar 21.

DOI:10.1159/000496606
PMID:30897579
Abstract

AIMS

To determine if findings at urodynamics prognosticate improvements in overactive bladder symptoms among women receiving mirabegron treatment.

METHODS

Before treatment, women completed a urodynamic investigation, a micturition diary and the Urinary Distress Inventory (UDI) with the irritative subscale UDIOAB. After 6 months mirabegron treatment, patients were clinically evaluated and completed the UDI. Associations were tested using regression analyses and nonparametric statistics.

RESULTS

Testing urodynamic variables for association with treatment effects in multiple linear regression analysis showed that lower volumes at first sensation to void significantly correlated with greater improvement in the UDIOAB after 6 months mirabegron treatment (B = 0.026, 95% CI 0.002-0.049, p = 0.034). Improvements in UDIOAB showed no correlation with presence of nocturia (p = 0.65), previous use of anticholinergics (p = 1), menopausal status (p = 1), any detrusor overactivity during filling (p = 1), phasic detrusor contractions during filling (p = 1), or detrusor overactivity during inhibition (p = 1).

CONCLUSIONS

We found limited support for clinically relevant associations between findings at urodynamics and subsequent treatment outcomes for mirabegron in routine clinical practice. Our findings do not support the role of these investigations as predictors of outcomes in patients with overactive bladder symptoms.

摘要

目的

确定尿动力学检查结果是否可以预测接受米拉贝隆治疗的女性膀胱过度活动症症状的改善情况。

方法

在治疗前,女性患者完成尿动力学检查、排尿日记和尿失禁困扰量表(UDI)及其刺激症状亚量表 UDIOAB。米拉贝隆治疗 6 个月后,患者进行临床评估并完成 UDI。使用回归分析和非参数统计检验关联。

结果

在多元线性回归分析中,测试尿动力学变量与治疗效果的关联,发现首次感觉排尿的较低容量与 6 个月米拉贝隆治疗后 UDIOAB 的改善显著相关(B = 0.026,95%CI 0.002-0.049,p = 0.034)。UDIOAB 的改善与夜间多尿(p = 0.65)、之前使用抗胆碱能药物(p = 1)、绝经状态(p = 1)、充盈期任何逼尿肌过度活动(p = 1)、充盈期相收缩性逼尿肌收缩(p = 1)或抑制期逼尿肌过度活动(p = 1)均无相关性。

结论

我们发现,在常规临床实践中,米拉贝隆治疗的尿动力学检查结果与随后的治疗结果之间存在有限的临床相关关联。我们的研究结果不支持这些检查作为膀胱过度活动症症状患者结局预测因素的作用。

相似文献

1
Urodynamics as a Prognosticator of Mirabegron Treatment Outcomes.尿动力学作为米拉贝隆治疗结局的预测因子。
Gynecol Obstet Invest. 2019;84(5):472-476. doi: 10.1159/000496606. Epub 2019 Mar 21.
2
Comparisons of the Clinical Outcomes and Urodynamic Effects of Mirabegron versus Tolterodine Treatment for Female Overactive Bladder Syndrome: A Subgroup Analysis of a Controlled, Randomised, Prospective Study.米拉贝隆与托特罗定治疗女性膀胱过度活动症的临床结局和尿动力学效应比较:一项对照、随机、前瞻性研究的亚组分析
Low Urin Tract Symptoms. 2018 Sep;10(3):215-220. doi: 10.1111/luts.12167. Epub 2017 Apr 23.
3
Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).米拉贝隆与索利那新联合治疗膀胱过度活动症患者的疗效和安全性:一项随机、双盲、剂量范围、2 期研究(Symphony)的结果。
Eur Urol. 2015 Mar;67(3):577-88. doi: 10.1016/j.eururo.2014.02.012. Epub 2014 Feb 19.
4
Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder in Asia.β3肾上腺素能受体激动剂米拉贝隆在亚洲膀胱过度活动症患者中进行的一项随机、双盲、平行组、安慰剂和活性药物对照的多中心研究结果。
Neurourol Urodyn. 2015 Sep;34(7):685-92. doi: 10.1002/nau.22645. Epub 2014 Aug 17.
5
Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability.米拉贝隆治疗膀胱过度活动症:疗效、安全性和耐受性评价。
Neurourol Urodyn. 2014 Jan;33(1):17-30. doi: 10.1002/nau.22505. Epub 2013 Oct 11.
6
Efficacy and safety of mirabegron for the treatment of neurogenic detrusor overactivity-Prospective, randomized, double-blind, placebo-controlled study.米拉贝隆治疗神经源性逼尿肌过度活动症的疗效和安全性:前瞻性、随机、双盲、安慰剂对照研究。
Neurourol Urodyn. 2018 Sep;37(7):2226-2233. doi: 10.1002/nau.23566. Epub 2018 Mar 31.
7
Comparison in the efficacy of fesoterodine or mirabegron add-on therapy to silodosin for patients with benign prostatic hyperplasia complicated by overactive bladder: A randomized, prospective trial using urodynamic studies.比较非那雄胺或米拉贝隆附加治疗对良性前列腺增生合并膀胱过度活动症患者的疗效:一项使用尿动力学研究的随机前瞻性试验。
Neurourol Urodyn. 2019 Mar;38(3):941-949. doi: 10.1002/nau.23935. Epub 2019 Feb 19.
8
A randomized, controlled trial of effectiveness and safety of management of OAB symptoms in elderly men and women with standard-dosed combination of solifenacin and mirabegron.索利那新与米拉贝隆标准剂量联合治疗老年男性和女性膀胱过度活动症症状的有效性和安全性的随机对照试验
Arch Gerontol Geriatr. 2015 Sep-Oct;61(2):212-6. doi: 10.1016/j.archger.2015.06.006. Epub 2015 Jun 25.
9
Urodynamic evaluation of the efficacy of mirabegron on storage and voiding functions in women with overactive bladder.米拉贝隆对膀胱过度活动症女性储尿和排尿功能疗效的尿动力学评估
Urology. 2015 Apr;85(4):786-90. doi: 10.1016/j.urology.2015.01.002. Epub 2015 Feb 20.
10
Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis.米拉贝隆对比抗胆碱能单药治疗或联合治疗用于治疗膀胱过度活动症的疗效和耐受性:一项系统评价和网络荟萃分析。
Eur Urol. 2018 Sep;74(3):324-333. doi: 10.1016/j.eururo.2018.03.020. Epub 2018 Apr 23.

引用本文的文献

1
The Utility of Urodynamic Studies in Neuro-Urological Patients.尿动力学检查在神经泌尿疾病患者中的应用
Biomedicines. 2023 Apr 9;11(4):1134. doi: 10.3390/biomedicines11041134.
2
Oral anticholinergic drugs versus placebo or no treatment for managing overactive bladder syndrome in adults.口服抗胆碱能药物与安慰剂或不治疗成人膀胱过度活动症。
Cochrane Database Syst Rev. 2023 May 9;5(5):CD003781. doi: 10.1002/14651858.CD003781.pub3.
3
Efficacy and tolerability of mirabegron compared with solifenacin for children with idiopathic overactive bladder: A preliminary study.
米拉贝隆对比索利那新治疗儿童特发性过度膀胱的疗效和耐受性:一项初步研究。
Investig Clin Urol. 2021 May;62(3):317-323. doi: 10.4111/icu.20200380. Epub 2021 Mar 19.